Skip to content

Syndax Pharmaceuticals

US · SNDX #2947 by market cap Listed 2016
8.72 -0.41 -4.49%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Financial Health how this is computed

Weak
  • Altman Z-Score is -3.42, below the 1.8 "distress zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +627.84% YoY

Margins

Gross margin
95.96%
Operating margin
-158.45%
Net margin
-165.60%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 1.52M1.52M1.52M139.71M0023.68M172.35M
Gross profit --------0022.85M165.38M
Selling & admin expenses 17.29M16.06M22.51M25.24M33.26M66.92M120.88M179.68M
Research & development 60.11M42.99M50.44M88.25M118.50M163.03M241.65M258.78M
Operating profit -75.88M-57.54M-71.42M26.22M-151.76M-229.95M-339.67M-273.08M
Pretax profit -73.96M-56.05M-73.16M24.93M-149.34M-209.36M-318.76M-285.42M
Tax ----------------
Net profit -73.96M-56.05M-73.16M24.93M-149.34M-209.36M-318.76M-285.42M
Basic EPS -3-2-20-2-3-4-3
Diluted EPS -2.92-1.84-1.870.46-2.46-2.98-3.72-3.29

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 83.35M62.33M298.86M448.40M489.79M580.88M603.06M528.08M
Cash & ST investments 80.91M59.78M293.07M439.94M475.80M570.70M572.88M394.07M
Inventory ----------0366.00K32.75M
Total assets 83.94M63.53M300.61M449.66M497.24M612.88M724.82M529.71M
Total current liabilities 16.11M18.37M18.87M20.68M29.07M58.10M103.55M120.12M
Short-term debt --478.00K2.60M362.00K439.00K1.05M12.60M472.00K
Long-term debt ----17.83M19.90M----331.57M343.91M
Total liabilities 30,891,000.0031,925,000.0048,425,000.0041,289,000.0029,787,000.0058,684,000.00436,692,000.00465,076,000.00
Total equity 53.05M31.60M252.19M408.37M467.45M554.20M288.12M64.63M
Retained earnings -439.42M-495.47M-568.63M-543.70M-693.04M-902.40M-1.22B-1.51B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow -68.53M-50.61M-71.26M29.13M-133.68M-160.60M-274.90M-322.98M
Depreciation & amortization 78.00K92.00K89.00K43.00K33.00K12.00K8.00K6.00K
Free cash flow -68.72M-50.61M-71.26M29.00M-133.68M-160.60M-274.90M-323.17M
Dividends paid ----------------
Stock buybacks / issuance 15.50M28.21M278.06M86.34M181.39M258.09M00
Ending cash balance 33.99M24.72M115.36M222.08M74.47M295.61M154.30M135.03M

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % -94.00-132.43-54.317.55-34.10-40.98-75.69-161.83
ROA % -66.90-76.02-42.336.64-31.54-37.72-47.66-45.50
ROIC % -94.00-129.68-52.587.95-34.64-44.96-79.22-148.94
5-year avg ROE % -------67.54-61.46-50.86-39.51-61.01
EBIT margin % -5,001.71-3,792.95-4,667.1719.20-----1,325.29-146.00
FCF / sales % ------20.76--------
Current ratio 5.183.3915.8421.6816.8510.005.824.40
Quick ratio 5.043.2615.5421.2916.519.845.673.87
Debt / assets 0.001.410.900.240.230.271.960.29
LT debt / equity --1.330.040.170.150.110.551.63
Interest coverage -----30.0414.13-46.61-1,005.54-63.67-7.45
Revenue CAGR (3Y) % 34.257.53-10.39351.59-----44.66--
Net income CAGR (3Y) % ----------------
FCF CAGR (3Y) % ----------------

Revenue breakdown most recent period

Business

Syndax Pharmaceuticals100.00%

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Syndax Pharmaceuticals discussion 0 comments

Add a comment